Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
Phase 2 N=154 A Study of LY2541546 in Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.065; 0.115; 0.142; 0.054 g/cm^2
N/A N=80 Micromechanical Modeling Using Low Magnitude Mechanical Stimulation
Bone Alteration
Primary: Change in Distal Tibia Bone Quality — 1.121; -2.141 percentage of change — p=0.0481
Phase 2 N=412 Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density
Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 for the Placebo and Denosumab Arms — -0.81; 4.41; 4.71; 6.69 Percent change — p=<0.001
Phase 2 N=419 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density · Postmenopausal Osteoporosis
Primary: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine — -0.1; 4.1; 7.1; 5.4 percent change — p=< 0.0001
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Phase 3 N=110 Effects of Anorexia Nervosa on Bone Mass in Adolescents
Anorexia Nervosa
Primary: Percent Change in Spine Bone Density Over the Study Duration (18 Months) — 2.6; 0.3 Percent change — p=<0.05
Phase 2 N=15 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Number of Participants With Normal/Abnormal Bone Histology — 15; 15; 15; 0 Participants
Phase 2 N=247 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Postmenopausal Osteoporosis
Primary: Cortical Thickness of Radius by XtremeCT Percent Change From Baseline at Month 12 — 2.4; 3.4; -.8 Percent Change from Baseline
Phase 3 N=424 A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
Leukemia, Lymphoblastic, Acute · Osteoporosis
Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
Phase 4 N=12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Osteoporosis · Bone Loss · Spinal Cord Injury
Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
N/A N=1,011 Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX
Osteoporosis
Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives
Phase 2 N=50 Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
Osteoporosis
Primary: Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) — -0.0026; 0.1299; 0.1196; -0.0029 gram per centimeter squared…
Phase 3 N=30 Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study
Bone Density · Bone Loss · Anorexia Nervosa
Primary: Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA) — 0.90; 0.87 g/cm^2 — p=0.009
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 3 N=276 Heartland Osteoporosis Prevention Study
Osteopenia
Primary: Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group. — 2098.7; 1993.3; 2001; 2105.89 mg^2/mm^4 — p=0.7
Phase 4 N=69 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…
Phase 4 N=66 A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
Post Menopausal Osteoporosis
Primary: Relative Percent Change in Serum C-terminal Telopeptide of Type 1 Collagen Concentration (sCTX) From Baseline to Day 3 — -70.16; -5.96 Percent change — p=< 0.0001
Phase 4 N=109 Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline in Urine N-telopeptide of Type 1 Collagen (NTx.) — 49.054; 44.460; 23.676; 34.183 nM BCE/mM Cr
Phase 4 N=50 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
Prostate Cancer
Primary: Percent Change in Bone Mineral Density — 0.1; -2; 0.2; -2.2 Percent Change — p=0.004
Phase 3 N=224 Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
Osteopenia
Primary: Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum — 4.62; 4.03; -2.24; 5.60 Percentage change in BMD
N/A N=22 Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Osteoporosis
Primary: Change in Bone Mineral Density (BMD) in HIP at 6 Months — -0.041; 0.011 grams/cm^2
Phase 2 N=52 Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents
HIV Infection
Primary: Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD — 14.4; 5.5; 15.9; 7.1 Percent change from baseline — p=<0.001
Phase 4 N=160 A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
Post-Menopausal Osteopenia
Primary: Relative Change From Baseline in Mean Bone Mineral Density (BMD) of the Lumbar Spine (L2 to L4) at Month 12 — -0.3941; 3.7285 Percentage — p=<0.0001
Phase 4 N=224 A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
Osteoporosis
Primary: Change in Lumbar Spine Areal Bone Mineral Density (BMD) — 0.094; 0.055 gram per square centimeter (g/cm^2) — p=<.0001